Last reviewed · How we verify
Matching Placebo to Sita/Met FDC
Matching Placebo to Sita/Met FDC is a DPP-4 inhibitor and biguanide combination Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Treatment of type 2 diabetes.
Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes.
Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | Matching Placebo to Sita/Met FDC |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | DPP-4 inhibitor and biguanide combination |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sita/Met FDC works by inhibiting the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones and enhancing the release of insulin in response to meals. Metformin, on the other hand, decreases glucose production in the liver and increases insulin sensitivity.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo to Sita/Met FDC CI brief — competitive landscape report
- Matching Placebo to Sita/Met FDC updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Matching Placebo to Sita/Met FDC
What is Matching Placebo to Sita/Met FDC?
How does Matching Placebo to Sita/Met FDC work?
What is Matching Placebo to Sita/Met FDC used for?
Who makes Matching Placebo to Sita/Met FDC?
What drug class is Matching Placebo to Sita/Met FDC in?
What development phase is Matching Placebo to Sita/Met FDC in?
What are the side effects of Matching Placebo to Sita/Met FDC?
What does Matching Placebo to Sita/Met FDC target?
Related
- Drug class: All DPP-4 inhibitor and biguanide combination drugs
- Target: All drugs targeting DPP-4
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Treatment of type 2 diabetes
- Compare: Matching Placebo to Sita/Met FDC vs similar drugs
- Pricing: Matching Placebo to Sita/Met FDC cost, discount & access